Clover Health Investments, Corp. (CLOV)
Clover Health Investments, Corp. (CLOV) Q2 Earnings Meet Estimates
Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.01 per share a year ago.
Clover Health Pre-Q2 Earnings Analysis: Buy, Sell or Hold the Stock?
CLOV's second-quarter results are likely to reflect strong Medicare Advantage membership growth and expansion and deeper integration of Clover Assistant.
All You Need to Know About Clover Health Investments (CLOV) Rating Upgrade to Strong Buy
Clover Health Investments (CLOV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Clover Health: Stars Are Aligning For GAAP Profitability In FY 2026
Clover reported impressive Q1 earnings with robust topline growth and improving profitability metrics thanks to a 30% YoY increase in its member base. Clover could see $95 million in additional revenues in FY 2026 without any member growth as a result of CMS increasing MA payouts by 5.1%. With Clover set to be eligible for a 5% quality bonus in 2026 thanks to its 4-star rating, I expect it to reach GAAP profitability in FY 2026.
CLOV Stock Rises as Q1 Earnings Beat Estimates, Revenues Up Y/Y
Clover Health's first-quarter 2025 results continue to benefit from the strength of its strong member retention. A decline in operating loss bodes well.
Clover Health Investments, Corp. (CLOV) Surpasses Q1 Earnings Estimates
Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of $0.05 per share a year ago.
Watch These 3 MedTech Stocks for Q1 Earnings: Beat or Miss?
MedTech companies' quarterly results are likely to reflect strength in customer demand. Let's see how FMS, MASI and CLOV are placed ahead of their earnings releases.
Clover Health: Expected Margin Contraction Is A Prelude To Exponential Growth
Clover Health Investments' AI capabilities are a major driver for its topline and bottom-line improvements in FY 2024. Clover Health's MCR in Q4 represented a decline from Q3, unlike past years, and rivaled its Q2 MCR, a sign of the impact of its AI capabilities. While Clover expects its margins to contract in FY 2025, its increased investments this year set it up for a highly profitable future starting from FY 2026, in my opinion.
Missed the Hims & Hers Rally? Clover Health Could Be Next
Shares of Hims & Hers Health Inc. NYSE: HIMS have made a splash in recent weeks, reaching a new all-time high of just under $73 per share. However, a few days later, most of the upside moved right back, crashing down to as low as $36 per share.
CLOV Q4 Earnings Beat Estimates, Sales Miss, Membership Rises
Clover Health's fourth-quarter 2024 results continue to benefit from the strength of its strong member retention. Strong revenue outlook bodes well.
Clover Health Investments, Corp. (CLOV) Q4 2024 Earnings Call Transcript
Clover Health Investments, Corp. (NASDAQ:CLOV ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Ryan Schmidt - Investor Relations Andrew Toy - Chief Executive Officer Peter Kuipers - Chief Financial Officer Conference Call Participants Jonathan Yong - UBS Tolf Cormanon - Craig Hallam Operator Ladies and gentlemen, good afternoon and welcome to the Clover Health Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Clover Health Investments, Corp. (CLOV) Tops Q4 Earnings Estimates
Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of $0.12 per share a year ago.
